miR-29a对于膝关节骨性关节炎大鼠滑膜损伤中的保护作用研究

摘要 目的：探讨miR-29a对于膝关节骨性关节炎（KOA）大鼠滑膜损伤中的保护作用研究。方法：采用前交叉韧带横断法（ACLT）建立KOA大鼠模型。大鼠注射microRNA阴性对照和miR-29a。通过实时定量聚合酶链反应（RT-qPCR）检测KOA滑膜组织和滑膜细胞中miR-29a的表达。RT-qPCR和蛋白免疫印迹试验检测Toll样受体4/髓样分化蛋白88/核因子κB（TLR4/Myd88/NF-κB）信号通路相关蛋白的表达。检测KOA滑膜组织及滑膜细胞中炎症因子的表达水平。结果：KOA滑膜组织和滑膜细胞中miR-29a表达下调。上调miR-29a可抑制KOA大鼠滑膜细胞的炎症反应,促使KOA大鼠的TLR4/Myd88/NF-κB信号通路失活。结论：上调miR-29a可通过TLR4/Myd88/NF-κB信号通路失活化抑制KOA大鼠滑膜细胞炎症反应,从而保护滑膜损伤。     

分子氢对糖尿病视网膜小胶质细胞的保护作用及其机制研究

目的:研究分子氢对糖尿病视网膜小胶质细胞的保护作用及其可能机制。方法:采用100 ng/m L的LPS诱导视网膜小胶质细胞,同时将两组细胞分别置于正常培养环境和含有饱和氢培养环境下培养36小时。RT-PCR检测小胶质细胞中miR-9、miR-21和miR-199的表达。Western Blot测定TLR4信号途径相关蛋白的表达。结果:miR-9、miR-21在分子氢作用后明显下调,而miR-199在分子氢作用后下调不明显。并且,小胶质细胞活化后TLR4途径相关信号蛋白的表达增加,在分子氢处理后Myd88和IKKβ蛋白的表达明显减少,而NF-κB蛋白的表达前后没有明显的变化。结论:分子氢对视网膜小胶质细胞的炎症损伤具有明显的保护作用,氢作为一种信号分子对Myd88介导的TLR4炎症信号通路的调节及通路中部分miRNA的调节作用可能是其抗炎作用的机制。     

乙肝病毒X 蛋白通过激活NF-κB 信号通路上调ABCG2 的表达

目的:研究乙肝病毒X蛋白(HBx)通过核因子-κB(NF-κB)信号通路对半转运蛋白(ABCG2)的调节作用。方法:用特异性的NF-κB信号通路阻断剂PDTC阻断NF-κB信号通路,荧光双标激光扫描共聚焦显微镜观察L02细胞系转染HBx基因前后及PDTC加入前后NF-κB信号通路的激活、失活情况,同时用Real-time PCR和Western Blot技术检测转染前后及PDTC加入前后ABCG2在mRNA及蛋白水平的表达变化。结果:以L02细胞为参照,转染HBx基因后的L02-HBx细胞NF-κB信号通路被激活,ABCG2 mRNA和蛋白水平分别增加3.62±0.15和4.61±0.73倍,差异有统计学意义(P<0.05);PDTC作用24h后L02/HBx细胞NF-κB信号通路阻断,ABCG2 mRNA和蛋白表达分别为2.15±0.32倍和2.37±0.55倍,与未加入PDTC作用的L02-HBx细胞相比均有统计学意义(P<0.05)。结论:NF-κB信号通路是HBx上调ABCG2表达的途径之一。     

TLR7在1型糖尿病大鼠肾缺血再灌注损伤中的作用研究

目的:探讨Toll样受体7(TLR7)介导的My D88/NF-κB信号通路在1型糖尿病大鼠肾缺血再灌注损伤中的作用。方法:雄性SD大鼠随机分为3组(n=6),糖尿病假手术组(DS),糖尿病缺血再灌注组(DIR),糖尿病缺血再灌注+氯喹预处理组(DIR+CQ)。采用腹腔注射链尿佐菌素65 mg/kg建立糖尿病模型,TLR7抑制剂氯喹预处理于糖尿病模型成功后第3周0.5%氯喹40 mg/kg进行腹腔注射,连续给药7天。于第四周采用双侧肾蒂夹闭25 min,再灌注48 h建立肾缺血再灌注损伤模型。取大鼠肾脏HE染色观察大鼠病理学结果,血标本测定血尿素氮(BUN)和血肌酐(Scr)水平,ELISA法检测白细胞介素6(IL-6)和肿瘤坏死因子-α(TNF-α),TUNEL法检测细胞凋亡,Western blot检测TLR7,My D88和NF-κB蛋白表达。结果:与DS组相比,DIR组肾小管肿胀,间质水肿,刷状缘丢失,空泡变性坏死,Paller评分升高(P0.01)。与DIR组相比,氯喹预处理可以改善肾损伤(P=0.017);与DS组相比,DIR组BUN,Scr,IL-6,TNF-α,细胞调亡指数(Apoptosis%),TLR7,My D88,NF-κB增高(P0.05);与DIR组相比,DIR+CQ组BUN,Scr,IL-6,TNF-α,Apoptosis%,TLR7,My D88,NF-κB降低(P0.05)。结论:TLR7介导的My D88/NF-κB信号通路参与糖尿病肾缺血再灌注损伤,氯喹通过抑制TLR7表达,阻断My D88/NF-κB信号通路,降低炎症反应,从而减轻1型糖尿病大鼠肾缺血再灌注损伤。     

大鼠海马神经元TLR4介导的MyD88依赖途径在神经炎症中的作用

目的:研究大鼠海马神经元是否有Toll样受体4(TLR4)介导的的髓样分化因子88(MyD88)依赖途径及该途径的激活在神经炎症中的作用。方法:采用体外培养7 d的新生大鼠海马神经元,细胞免疫荧光双标法鉴定海马神经元纯度。用TLR4配体脂多糖(LPS)或TLR4抗体预处理海马神经元,以激活或阻断TLR4的作用。实时定量PCR(RT-qPCR)方法检测海马神经元中MyD88、肿瘤坏死因子受体相关因子6(TRAF6)mRNA的表达;Westernblot方法测定海马神经元MyD88和TRAF6蛋白水平;细胞免疫荧光双标法观察海马神经元中核因子κB/P65(NF-κB/P65)的表达定位及TLR4激活或阻断后NF-κB/P65核易位情况;ELISA检测培养上清液中肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)和一氧化氮(NO)的水平。结果:LPS能上调海马神经元MyD88和肿瘤坏死因子受体相关因子(TRAF6)mRNA水平;促使NF-κB/P65转位至核;增加MyD88和TRAF6蛋白的表达;增加海马神经元培养上清中TNF-α、IL-1β和NO含量;TLR4抗体预处理能减弱LPS对海马神经元NF-κB/P65核易位作用及降低培养上清中TNF-α、IL-1β和NO的水平。结论:大鼠海马神经元有TLR4介导的的MyD88依赖途径,该途径的激活能导致TNF-α、IL-lβ和NO含量的增加。海马神经元TLR4介导的MyD88依赖途径参与了神经炎症反应,神经元不是神经炎症反应中的被动者。     

基于TLR4/MyD88/NF-κB信号通路探讨安肠汤联合艾灸治疗肝郁脾虚证腹泻型肠易激综合征的疗效及其机制

摘要 目的：基于Toll样受体4（TLR4）/髓样分化因子88（MyD88）/核因子-κB（NF-κB）信号通路探讨安肠汤联合艾灸治疗肝郁脾虚证腹泻型肠易激综合征（IBS）的疗效及其机制。方法：采用随机数字表法,将广州中医药大学第一附属医院在2019年4月~2022年12月期间收治的108例腹泻型IBS患者分为对照组（常规药物联合艾灸治疗,n=54）和研究组（对照组基础上接受安肠汤治疗,n=54）。对比两组疗效、中医证候总积分、IBS症状严重程度问卷（IBS-SSS）评分、肠屏障功能指标、TLR4/MyD88/NF-κB信号通路相关信使核糖核酸（mRNA）表达水平。结果：研究组的临床总有效率高于对照组（P<0.05）。两组治疗后中医证候总积分、IBS-SSS评分下降,且研究组低于对照组（P<0.05）。两组治疗后肠脂肪酸结合蛋白（IFABP）、D-乳酸及二胺氧化酶（DAO）下降,且研究组低于对照组（P<0.05）。两组治疗后TLR4、MyD88、NF-κB mRNA表达下降,且研究组低于对照组（P<0.05）。结论：安肠汤联合艾灸治疗肝郁脾虚证腹泻型IBS患者,可有效改善临床症状和肠屏障功能,疗效较好,可能与调节TLR4/MyD88/NF-κB信号通路有关。     

乙肝病毒X蛋白通过激活NF-κB信号通路上调ABCG2的表达

目的：研究乙肝病毒X蛋白（HBx）通过核因子-κB（NF-κB）信号通路对半转运蛋白（ABCG2）的调节作用。方法：用特异性的NF-κB信号通路阻断剂PDTC阻断NF-κB信号通路,荧光双标激光扫描共聚焦显微镜观察L02细胞系转染HBx基因前后及PDTC加入前后NF-κB信号通路的激活、失活情况,同时用Real-time PCR和Western Blot技术检测转染前后及PDTC加入前后ABCG2在mRNA及蛋白水平的表达变化。结果：以L02细胞为参照,转染HBx基因后的L02-HBx细胞NF-κB信号通路被激活,ABCG2 mRNA和蛋白水平分别增加3.62±0.15和4.61±0.73倍,差异有统计学意义（P〈0.05）;PDTC作用24h后L02/HBx细胞NF-κB信号通路阻断,ABCG2 mRNA和蛋白表达分别为2.15±0.32倍和2.37±0.55倍,与未加入PDTC作用的L02-HBx细胞相比均有统计学意义（P〈0.05）。结论：NF-κB信号通路是HBx上调ABCG2表达的途径之一。     

MyD88抑制乙型肝炎病毒复制依赖活化NF-κB信号通路

目的 研究髓样细胞分化蛋白(MyD88)抗乙型肝炎病毒(HBV)效应的作用机制。方法 构建MyD88的截短突变体,获得核因子kappa B(NF-κB)超抑制剂IkBa-SR或者NF-κB信号通路激活剂IKKα/IKKβ的表达质粒,分别与HBV复制型质粒瞬时转染Huh7细胞,检测细胞上清液中HBeAg,HBsAg的表达以及胞质中HBV复制中间体DNA的含量,并以NF-κB依赖的荧光素酶报道系统检测它们活化NF-κB的程度。结果 MyD88全长蛋白和2个截短突变体M(1-151)、M(151-296)活化NF-κB的程度与其抑制HBV蛋白以及复制中间体DNA合成的能力相一致。与空载相比,表达NF-κB信号通路激活剂IKKα/IKKβ的质粒共同瞬转细胞后,转染MyD88和HBV表达质粒的细胞中NF-κB的通路明显活化,同时HBV core蛋白的合成显著降低;而NF-κB的超抑制剂IκBα-SR共同瞬转的细胞中core蛋白的表达量显著增加,检测细胞培养上清液中HBeAg和HBsAg及胞质中HBV复制中间体DNA的合成,得到相似结果。结论 NF-κB信号通路的活化在MyD88抑制HBV复制中发挥了关键作用     

单纯疱疹病毒US3衣壳蛋白在TRAF6泛素化时或之前抑制Toll样受体2信号通路

单纯疱疹病毒（HSV ）能通过多种策略来调节宿主免疫反应。通过对 HSV开放读码框架的筛选发现, HSV编码的额外蛋白能影响核因子κB（NF-κB）信号通路,确定了病毒US3衣壳蛋白是NF-κB信号通路的抑制剂。该研究发现,在感染早期 US3蛋白能抑制病毒感染引起的Toll样受体2（TLR2）信号通路激活。US3在转染细胞中过表达能抑制酵母多糖引起的 TLR2信号通路激活,且这种抑制作用发生在MyD88的下游和p65的上游。在TLR2信号通路中,TRAF6的泛素化至关重要。使用US3-null和US3激酶突变病毒株,证明HSV US3蛋白能降低TRAF6泛素化,且US3激酶活性是这种作用所必需。结果提示,US3是有效抑制TLR2信号通路所必需且发生在TRAF6泛素化时或之前。     

过表达miR-31对结肠炎模型小鼠TLR4/NF-κB信号通路及凋亡蛋白的调控

目的: 探讨miR-31对DSS诱发结肠炎小鼠TLR4/NF-κB信号通路和凋亡相关蛋白的影响。方法: ①小鼠结肠炎实验:用1%葡聚糖硫酸钠(DSS)诱发小鼠溃疡性结肠炎(UC)。14只FVB非转基因小鼠随机分为control组(n=6),DSS组(n=8),16只FVB miR-31转基因小鼠随机分为miR-31过表达组(n=8),miR-31过表达+DSS 组(n=8),DSS溶于水后通过饮水给予小鼠。DSS组和miR-31+DSS组第一周饮用1%DSS水,第二周饮用正常无菌水,第三周饮用1%DSS水,如此5周后造模完成,之后留取小鼠的结肠组织,通过Western blot和IHC检测小鼠结肠组织NF-κB p65、TLR4、Bax、Bcl-2蛋白的表达;TUNEL检测小鼠结肠组织细胞凋亡。②细胞培养实验:在人结肠上皮细胞系HCT 116细胞中通过脂质体转染的方法转染miR-31 mimic和inhibitor,使miR-31过表达或敲低,每组均进行三次重复,48 h后收取细胞,通过Western blot检测NF-κB p65、TLR4蛋白的表达。结果: ①动物实验中,与control组相比,小鼠结肠组织中DSS组和miR-31过表达组NF-κB p65、TLR4蛋白表达水平和凋亡细胞指数均显著升高(P＜0.05或P＜0.01),Bcl-2/Bax比值显著降低(P＜0.05或P＜0.01);且与DSS组相比,miR-31+DSS组NF-κB p65、TLR4蛋白表达水平和凋亡细胞指数也显著升高(P＜0.01),Bcl-2/Bax比值显著降低(P＜0.01)。②细胞实验中,与control组相比, HCT 116细胞过表达miR-31组的NF-κB p65、TLR4蛋白表达水平均显著升高(P＜0.05或P＜0.01),敲低miR-31组的NF-κB p65、TLR4蛋白表达水平下降(P＜0.05)。结论: miR-31通过促进TLR4/NF-κB信号通路和介导肠上皮细胞凋亡促进结肠炎的发展。     

七鳃鳗myd88基因的生物学特性及其下游分子的表达模式分析

髓样分化因子88 (Myeloid differentiation factor 88, MYD88)是Toll样受体(Toll-like receptor, TLR)信号通路的关键接头分子, 在先天性免疫和适应性免疫中都起到重要作用。为了揭示七鳃鳗Myd88的生物学功能, 研究首次从七鳃鳗(Lampetra japonica)中克隆了myd88基因, 其ORF为852 bp, 共编码283个氨基酸, 推测的分子量为32.432 kD, 等电点为6.25, 无信号肽。多重序列比对表明七鳃鳗Myd88的氨基酸序列与其他物种同源性较高, 具有高度保守的N端死亡结构域和C端的TIR结构域的Box1、Box2和Box3基序。实时荧光定量PCR分析表明: myd88基因在七鳃鳗各组织中均有低水平转录表达, 鳃中表达量最高, 其次是肌肉、髓和肾。脂多糖(LPS)体内刺激七鳃鳗后, 七鳃鳗myd88在白细胞中表达量升高最显著, 其次是在鳃中的表达量也明显升高, 表明七鳃鳗Myd88参与七鳃鳗的抗菌免疫过程。此外, LPS刺激七鳃鳗还能诱导TLR信号通路Myd88依赖途径的下游信号分子Irak1、Traf6、Ikkβ和Nfkb在各组织中的转录表达。研究结果表明七鳃鳗中可能存在TLR/Myd88信号通路, 为进一步探究该信号通路参与免疫应答的起源与进化奠定了基础。     

Identification and characterization of a myeloid differentiation factor 88 (MyD88) cDNA from Zhikong scallop Chlamys farreri

Myeloid differentiation factor 88 (MyD88) is a universal and essential adapter for the TLR/IL-1R family. In this report, the first mollusk Myd88 ortholog (named as CfMyd88) was cloned from Zhikong scallop (Chlamys farreri). The full-length cDNA of CfMyd88 was of 1554 bp, including a 5'-terminal untranslated region (UTR) of 427 bp, a polyA tail, and an open reading frame (ORF) of 1104 bp encoding a polypeptide of 367 amino acids containing the typical TLR and IL-1R-related (TIR) domain and death domain (DD). Homology analysis revealed that the predicted amino acid sequence of CfMyd88 was homologous to a variety of previously identified Myd88s with more than 30% identity. The temporal expressions of CfMyd88 mRNA in the mixed primary cultured haemocytes stimulated by lipopolysaccharide (LPS) and peptidoglycans (PGN) were measured by real-time RT-PCR system. The mRNA expression of CfMyd88 decreased after stimulation with both LPS and PGN, and the lowest level was about 1/3 times (at 6 h) and 1/10 times (at 9 h) to that in the control group, respectively. The expression then recovered and was upregulated to two-fold at 9 h after LPS stimulation or to the original level at 12 h after PGN stimulation. The results suggest that the MyD88-dependent signaling pathway exists in scallop and was involved in the defense system.     

Amelioration of Murine Passive Immune Thrombocytopenia by IVIg and a Therapeutic Monoclonal CD44 Antibody Does Not Require the Myd88 Signaling Pathway

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by a low platelet count and the production of anti-platelet antibodies. The majority of ITP patients have antibodies to platelet integrin α_IIbβ₃ (GPIIbIIIa) which can direct platelet phagocytosis by macrophages. One effective treatment for patients with ITP is intravenous immunoglobulin (IVIg) which rapidly reverses thrombocytopenia. The exact mechanism of IVIg action in human patients is unclear, although in mouse models of passive ITP, IVIg can rapidly increase platelet counts in the absence of adaptive immunity. Another antibody therapeutic that can similarly increase platelet counts independent of adaptive immunity are CD44 antibodies. Toll-like receptors (TLRs) are pattern recognition receptors which play a central role in helping direct the innate immune system. Dendritic cells, which are notable for their expression of TLRs, have been directly implicated in IVIg function as an initiator cell, while CD44 can associate with TLR2 and TLR4. We therefore questioned whether IVIg, or the therapeutic CD44 antibody KM114, mediate their ameliorative effects in a manner dependent upon normal TLR function. Here, we demonstrate that the TLR4 agonist LPS does not inhibit IVIg or KM114 amelioration of antibody-induced thrombocytopenia, and that these therapeutics do not ameliorate LPS-induced thrombocytopenia. IVIg was able to significantly ameliorate murine ITP in C3H/HeJ mice which have defective TLR4. All known murine TLRs except TLR3 utilize the Myd88 adapter protein to drive TLR signaling. Employing Myd88 deficient mice, we found that both IVIg and KM114 ameliorate murine ITP in Myd88 deficient mice to the same extent as normal mice. Thus both IVIg and anti-CD44 antibody can mediate their ameliorative effects in murine passive ITP independent of the Myd88 signaling pathway. These data help shed light on the mechanism of action of IVIg and KM114 in the amelioration of murine ITP.     

The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling

Interferon regulatory factors (IRFs) are critical components of virus-induced immune activation and type I interferon regulation. IRF3 and IRF7 are activated in response to a variety of viruses or after engagement of Toll-like receptor (TLR) 3 and TLR4 by double-stranded RNA and lipopolysaccharide, respectively. The activation of IRF5, is much more restricted. Here we show that in contrast to IRF3 and IRF7, IRF5 is not a target of the TLR3 signaling pathway but is activated by TLR7 or TLR8 signaling. We also demonstrate that MyD88, interleukin 1 receptor-associated kinase 1, and tumor necrosis factor receptor-associated factor 6 are required for the activation of IRF5 and IRF7 in the TLR7 signaling pathway. Moreover, ectopic expression of IRF5 enabled type I interferon production in response to TLR7 signaling, whereas knockdown of IRF5 by small interfering RNA reduced type I interferon induction in response to the TLR7 ligand, R-848. IRF5 and IRF7, therefore, emerge from these studies as critical mediators of TLR7 signaling.     

HSV-2 Increases TLR4-Dependent Phosphorylated IRFs and IFN-β Induction in Cervical Epithelial Cells

Our previous studies demonstrated that HSV-2 infection up-regulates TLR4 expression and induces NF-kB activity, thereby facilitating innate immune response in human cervical epithelial cells. This process requires involvement of TLR4 adaptors, Mal and MyD88. In the current study, we found that HSV-2 infection increases levels of phosphoryalted IRF3 and IRF7, then regulating expression of type I IFN. As expected, these changes induced by HSV-2 infection depended upon TLR4. Knockdown of TRIF and/or TRAM by siRNAs indicated that TRIF/TRAM might be involved in expression of IFN-β. Our results demonstrate for the first time that IRF3 and IRF7 are both involved in inducing TLR4-dependent IFN-β expression in response to HSV-2 in its primary infected genital epithelial cells. Thus, TLR4-Mal/MyD88 and TLR4-TRIF/TRAM signaling may synergize and/or cooperate in innate immune response of cervical epithelial cells to HSV-2 infection.     

Human Parainfluenza Virus Type 2 V Protein Inhibits TRAF6-Mediated Ubiquitination of IRF7 To Prevent TLR7- and TLR9-Dependent Interferon Induction

Paramyxovirus V proteins block Toll-like receptor 7 (TLR7)- and TLR9-dependent signaling leading to alpha interferon production. Our recent study has provided evidence that interaction of the V proteins with IRF7 is important for the blockade. However, the detailed mechanisms still remain unclear. Here we reexamined the interaction of the human parainfluenza virus type 2 (HPIV2) V protein with signaling molecules involved in TLR7/9-dependent signaling. Immunoprecipitation experiments in HEK293T cells transfected with V protein and one of the signaling molecules revealed that the V protein interacted with not only IRF7 but also TRAF6, IKKα, and MyD88. Whereas overexpression of TRAF6 markedly enhanced the level of V protein associating with IRF7, IKKα, and MyD88 in HEK293T cells, the level of V protein associating with TRAF6 was little affected by overexpression of IRF7, IKKα, and MyD88. Moreover, knockdown or knockout of endogenous TRAF6 in HEK293T or mouse embryonic fibroblast cells resulted in dissociation of the V protein from IRF7, IKKα, and MyD88. These results demonstrate that binding of the V protein to IRF7, IKKα, and MyD88 is largely indirect and mediated by endogenous TRAF6. It was found that the V protein inhibited TRAF6-mediated lysine 63 (K63)-linked polyubiquitination of IRF7, which is prerequisite for IRF7 activation. Disruption of the tryptophan-rich motif of the V protein significantly affected its TRAF6-binding efficiency, which correlated well with the magnitude of inhibition of K63-linked polyubiquitination and the resultant activation of IRF7. Taken together, these results suggest that the HPIV2 V protein prevents TLR7/9-dependent interferon induction by inhibiting TRAF6-mediated K63-linked polyubiquitination of IRF7.